← Back to Search

Neuromodulator

Nerve Block for Heart Rhythm Problems

Phase < 1
Recruiting
Research Sponsored by University of Pennsylvania
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Planned catheter based VT ablation
Age at least 18 years
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 minutes following stellate ganglion block
Awards & highlights

Study Summary

This trial looks at whether a nerve block can help treat heart rhythm problems.

Who is the study for?
This trial is for adults at least 18 years old who are scheduled to have a catheter-based procedure to correct rapid, irregular heartbeats known as ventricular tachycardia. Pregnant individuals, those with conditions that make the stellate ganglion block or VT ablation unsafe, and people allergic to certain local anesthetics cannot participate.Check my eligibility
What is being tested?
The study is examining how a nerve-blocking injection called Stellate Ganglion Block (SGB) affects the electrical activity of the heart in patients with ventricular tachycardia. It's a forward-looking study tracking participants over time.See study design
What are the potential side effects?
Potential side effects of SGB may include discomfort at the injection site, changes in blood pressure, headache, drooping eyelid on one side (Horner's syndrome), difficulty swallowing, and voice changes.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I am scheduled for a procedure to treat irregular heartbeats using catheters.
Select...
I am 18 years old or older.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 minutes following stellate ganglion block
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 minutes following stellate ganglion block for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Ventricular Effective Refractory Period
Secondary outcome measures
Neuropeptides
Ventricular Arrhythmia Inducibility

Side effects data

From 2022 Phase 1 & 2 trial • 20 Patients • NCT05445921
100%
Horner syndrome
45%
Hoarseness
35%
Globus
25%
Brief lightheadedness
20%
Mild shortness of breath
20%
Numbness of the face
15%
Nasal congestion
15%
Pain at the injection site
15%
Fatigue
5%
Weakness of the arm
5%
Tightness of the shoulder
5%
Tightness of the back
5%
Cough
5%
Chest heaviness
5%
Bruising of the injection site
5%
Headache
5%
Palpitations
5%
Arm heaviness
5%
Weakness of the neck/back
100%
80%
60%
40%
20%
0%
Study treatment Arm
Stellate Ganglion Block

Trial Design

1Treatment groups
Experimental Treatment
Group I: Stellate ganglion blockExperimental Treatment1 Intervention
All subjects will undergo stellate ganglion block during their VT ablation procedure
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Stellate Ganglion Block
2020
Completed Phase 2
~200

Find a Location

Who is running the clinical trial?

University of PennsylvaniaLead Sponsor
1,994 Previous Clinical Trials
42,879,236 Total Patients Enrolled

Media Library

Stellate Ganglion Block (Neuromodulator) Clinical Trial Eligibility Overview. Trial Name: NCT05377216 — Phase < 1
Ventricular Tachycardia Research Study Groups: Stellate ganglion block
Ventricular Tachycardia Clinical Trial 2023: Stellate Ganglion Block Highlights & Side Effects. Trial Name: NCT05377216 — Phase < 1
Stellate Ganglion Block (Neuromodulator) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05377216 — Phase < 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment enrolling participants at present?

"Clinicaltrials.gov demonstrates that this clinical trial, initially posted on September 1st 2022, is actively seeking participants. The latest update was made on the 28th of September."

Answered by AI

How many participants is the clinical trial recruiting at this time?

"Affirmative. Clinicaltrials.gov confirms that this clinical study, which was first posted on September 1st 2022, is currently searching for qualified participants. Specifically, the trial requires 20 people to be enrolled from a single medical centre."

Answered by AI
~13 spots leftby Jun 2027